Table 1

Hematology and platelet glycoprotein expression in control and INU1-treated mice

ControlINU1
HCT, % 0.53 ± 0.02 0.49 ± 0.04 
WBC, ×106 11.1 ± 1.2 11.0 ± 1.7 
CLEC-2 119 ± 10 14 ± 1 
GPIb 398 ± 5 391 ± 19 
GPV 354 ± 5 364 ± 14 
GPIX 550 ± 13 563 ± 20 
CD9 1496 ± 27 1338 ± 66 
GPVI 61 ± 3 56 ± 3 
α2 76 ± 5 69 ± 1 
β1 173 ± 11 165 ± 12 
αIIbβ3 888 ± 40 854 ± 51 
ControlINU1
HCT, % 0.53 ± 0.02 0.49 ± 0.04 
WBC, ×106 11.1 ± 1.2 11.0 ± 1.7 
CLEC-2 119 ± 10 14 ± 1 
GPIb 398 ± 5 391 ± 19 
GPV 354 ± 5 364 ± 14 
GPIX 550 ± 13 563 ± 20 
CD9 1496 ± 27 1338 ± 66 
GPVI 61 ± 3 56 ± 3 
α2 76 ± 5 69 ± 1 
β1 173 ± 11 165 ± 12 
αIIbβ3 888 ± 40 854 ± 51 

Hematocrit (HCT) in percentage and white blood cell counts (WBCs) per milliliter for control and INU1-treated mice (day 5) were analyzed with an automated blood analyzer (Sysmex; n=6 mice per group). Expression of glycoproteins on the platelet surface was determined by flow cytometry. Diluted whole blood from the indicated mice was incubated with fluorescein isothiocyanate–labeled antibodies at saturating concentrations for 15 minutes at reverse transcription and platelets were analyzed directly. Results are expressed as mean fluorescence intensity ± SD for 6 mice per group.

or Create an Account

Close Modal
Close Modal